RU2763346C2 - Фармацевтическая композиция для предупреждения или лечения острого миелоидного лейкоза или метастатического рака молочной железы - Google Patents

Фармацевтическая композиция для предупреждения или лечения острого миелоидного лейкоза или метастатического рака молочной железы Download PDF

Info

Publication number
RU2763346C2
RU2763346C2 RU2020115581A RU2020115581A RU2763346C2 RU 2763346 C2 RU2763346 C2 RU 2763346C2 RU 2020115581 A RU2020115581 A RU 2020115581A RU 2020115581 A RU2020115581 A RU 2020115581A RU 2763346 C2 RU2763346 C2 RU 2763346C2
Authority
RU
Russia
Prior art keywords
compound
biindolinylidene
imino
ethoxy
flt3
Prior art date
Application number
RU2020115581A
Other languages
English (en)
Russian (ru)
Other versions
RU2020115581A3 (enExample
RU2020115581A (ru
Inventor
Ён Чхул КИМ
Пён Хва ЧОН
Original Assignee
Пелемед Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пелемед Ко., Лтд. filed Critical Пелемед Ко., Лтд.
Publication of RU2020115581A3 publication Critical patent/RU2020115581A3/ru
Publication of RU2020115581A publication Critical patent/RU2020115581A/ru
Application granted granted Critical
Publication of RU2763346C2 publication Critical patent/RU2763346C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2020115581A 2017-10-31 2018-10-30 Фармацевтическая композиция для предупреждения или лечения острого миелоидного лейкоза или метастатического рака молочной железы RU2763346C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170144142 2017-10-31
KR10-2017-0144142 2017-10-31
PCT/KR2018/013051 WO2019088677A1 (ko) 2017-10-31 2018-10-30 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물

Publications (3)

Publication Number Publication Date
RU2020115581A3 RU2020115581A3 (enExample) 2021-12-02
RU2020115581A RU2020115581A (ru) 2021-12-02
RU2763346C2 true RU2763346C2 (ru) 2021-12-28

Family

ID=66333236

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020115581A RU2763346C2 (ru) 2017-10-31 2018-10-30 Фармацевтическая композиция для предупреждения или лечения острого миелоидного лейкоза или метастатического рака молочной железы

Country Status (12)

Country Link
US (1) US11370779B2 (enExample)
EP (1) EP3705474A4 (enExample)
JP (1) JP7005779B2 (enExample)
KR (1) KR102247795B1 (enExample)
CN (1) CN111542513A (enExample)
AU (1) AU2018358582B2 (enExample)
BR (1) BR112020008499A2 (enExample)
CA (1) CA3080900C (enExample)
MX (1) MX2020004374A (enExample)
PH (1) PH12020550491A1 (enExample)
RU (1) RU2763346C2 (enExample)
WO (1) WO2019088677A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2800861C1 (ru) * 2023-01-17 2023-07-31 Федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов имени Патриса Лумумбы" (РУДН) Способ получения 3-фенилдиазенил-1Н,1'Н-[2,3']бииндолов

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021552551A1 (en) 2019-04-26 2022-06-20 Unilever Ip Holdings B V Hair conditioning composition
CN110305056A (zh) * 2019-05-22 2019-10-08 西北大学 靛玉红新衍生物及其药用用途
WO2021090172A1 (en) * 2019-11-04 2021-05-14 Ck Biotechnology Co. Compositions and methods for suppressing and/or treating neurodegenerative diseases and/or a clinical condition thereof
KR102296440B1 (ko) * 2019-12-06 2021-09-02 주식회사 펠레메드 신규한 인디루빈 유도체 및 이의 용도
KR102443617B1 (ko) * 2019-12-06 2022-09-16 광주과학기술원 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물
KR102325607B1 (ko) 2020-02-20 2021-11-12 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
KR20210106155A (ko) 2020-02-20 2021-08-30 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 페닐카르보노히드라조노일 디시아나이드 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
KR102278176B1 (ko) 2020-02-20 2021-07-16 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조디옥솔 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
US20220079934A1 (en) * 2020-09-17 2022-03-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pain
KR102744517B1 (ko) * 2022-02-14 2024-12-19 주식회사 펠레메드 신규한 헤테로비시클릭 잔기를 갖는 인디루빈 유도체 및 이의 용도
EP4674839A1 (en) * 2023-02-28 2026-01-07 CK Regeon Inc. Novel indoline derivative and use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061555A1 (en) * 1999-04-12 2000-10-19 Gerhard Eisenbrand Indigoid bisindole derivatives
WO2005070416A1 (en) * 2004-01-27 2005-08-04 Anygen Co., Ltd. Indirubin derivatives having anticancer property against human cancer cell me
RU2341523C2 (ru) * 2003-01-31 2008-12-20 Авентис Фарма С.А. Новые производные цикломочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ
EP2518139A1 (en) * 2011-04-27 2012-10-31 Universitätsklinikum Jena Use of indirubin derivatives for producing pluripotent stem cells
US20140275168A1 (en) * 2013-03-14 2014-09-18 City Of Hope Indirubin derivatives, and uses thereof
US20150259288A1 (en) * 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5448455B2 (ja) 2005-12-23 2014-03-19 サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク （セ エン エール エス） 新規３’−，７−置換インジルビンおよびそれらの適用
EP2149553B1 (en) 2008-08-01 2011-10-19 Centre National de la Recherche Scientifique 3', 6-substituted indirubins and their biological applications
KR101180030B1 (ko) * 2010-02-05 2012-09-05 광주과학기술원 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체
WO2013142817A2 (en) * 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
AU2014236370C1 (en) * 2013-03-14 2019-01-17 City Of Hope 5-bromo-indirubins

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061555A1 (en) * 1999-04-12 2000-10-19 Gerhard Eisenbrand Indigoid bisindole derivatives
RU2341523C2 (ru) * 2003-01-31 2008-12-20 Авентис Фарма С.А. Новые производные цикломочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ
WO2005070416A1 (en) * 2004-01-27 2005-08-04 Anygen Co., Ltd. Indirubin derivatives having anticancer property against human cancer cell me
EP2518139A1 (en) * 2011-04-27 2012-10-31 Universitätsklinikum Jena Use of indirubin derivatives for producing pluripotent stem cells
US20140275168A1 (en) * 2013-03-14 2014-09-18 City Of Hope Indirubin derivatives, and uses thereof
US20150259288A1 (en) * 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cheng, X., Merz, K.-H., Vatter, S., Zeller, J., et al. "Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule", Journal of Medicinal Chemistry, 22.06.2017, vol. 60(12), p.4949-4962;. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2800861C1 (ru) * 2023-01-17 2023-07-31 Федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов имени Патриса Лумумбы" (РУДН) Способ получения 3-фенилдиазенил-1Н,1'Н-[2,3']бииндолов

Also Published As

Publication number Publication date
AU2018358582A1 (en) 2020-05-07
BR112020008499A2 (pt) 2020-10-20
PH12020550491A1 (en) 2021-01-11
AU2018358582B2 (en) 2021-06-10
WO2019088677A1 (ko) 2019-05-09
CA3080900C (en) 2022-10-25
KR102247795B9 (ko) 2023-04-12
US20200270229A1 (en) 2020-08-27
CA3080900A1 (en) 2019-05-09
EP3705474A1 (en) 2020-09-09
EP3705474A4 (en) 2021-06-09
KR20190049584A (ko) 2019-05-09
MX2020004374A (es) 2020-11-11
RU2020115581A3 (enExample) 2021-12-02
KR102247795B1 (ko) 2021-05-04
RU2020115581A (ru) 2021-12-02
JP2021501208A (ja) 2021-01-14
CN111542513A (zh) 2020-08-14
JP7005779B2 (ja) 2022-02-10
US11370779B2 (en) 2022-06-28

Similar Documents

Publication Publication Date Title
KR102247795B1 (ko) 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물
JP7485810B2 (ja) 癌を処置する方法
JP7431309B2 (ja) 血液悪性腫瘍患者の治療方法
ES2872553T3 (es) Inhibidores de lisil oxidasa tipo-2 y usos de los mismos
WO2013162727A1 (en) Methods and compositions for raf kinase mediated diseases
TW200307535A (en) Therapeutic agent for cancer
WO2013101281A1 (en) Methods and compositions for treating parkinson's disease
CN108025191A (zh) 治疗癌症的方法
RS57144B1 (sr) Prolekovi kvinazolin amina kao inhibitori kinaze
EP2685980B1 (en) Methods and use of bifunctional enzyme-building clamp-shaped molecules
US20250235426A1 (en) Pharmaceutical Combination and Use Thereof
EP3680233A1 (en) NOVEL AMIDE COMPOUND, AND Pin1 INHIBITOR, THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES AND THERAPEUTIC AGENT FOR CANCER THAT USE THE SAME
JP5100619B2 (ja) ロキソプロフェン含有医薬製剤１
KR20210047850A (ko) 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물
EP4370125A1 (en) Phthalazinone-based parp-1 inhibitors
US20150353524A1 (en) Pyridine compounds used as pi3 kinase inhibitors
AU2017282659A1 (en) Therapeutic compounds
JP2002293745A (ja) 慢性関節リウマチ治療剤
KR20240141067A (ko) 표적 단백질 및 표적 분해 단백질에 결합하는 화합물, 이를 유효성분으로 함유하는 약학적 조성물, 및 이의 용도
CN115721649A (zh) 抑制突变型egfr的化合物及其应用
KR102914180B1 (ko) 바이사이클 유도체를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
KR102051449B1 (ko) 결핵균 유래의 4'-포스포판테테이닐 트랜스퍼레이즈 효소 저해물질 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물
KR101995533B1 (ko) [1,2,4]트리아졸로[4,3-a]퀴노잘린 아미노 페닐 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 BET 단백질 관련 질환의 예방 또는 치료용 약학적 조성물